Angitia Biopharmaceuticals
PrivateLast Round
Series D
Feb 5, 2026
Total Funding Raised
$406M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Angitia Biopharmaceuticals is a biotechnology company that discovers and develops innovative biologic therapies for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Angitia Biopharmaceuticals Comparables
Compare Angitia Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DiscGenics | 82% | |
| Transcenta Holding | 78% | |
| Mesentech Inc. | 78% | |
Angitia Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Feb 5, 2026 | ||||
| Series C | Dec 11, 2024 | ||||
| Series B Extension | Jan 1, 2024 | ||||
| Series B Extension | Oct 25, 2023 | ||||
| Series B | Oct 31, 2021 | ||||
Series A | Aug 18, 2020 |
Key People
Founding team and executive leadership
Angitia Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed Asia | Series A |
| Bain Capital Life Sciences | Series D, Series C |
| Janus Henderson Group | Series D, Series C |
| RA Capital Management | Series D |
| Oriza Holdings | Series B, Series B Extension |
| Firstred Capital | Series B |
| Hillhouse Investment | Series D, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 3, 2026
Studying 3 biologic product candidates for osteoporosis, OI, and spinal fusion.
- Feb 5, 2026
$130M round completed.
Angitia Biopharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Angitia Biopharmaceuticals's valuation, stock price, and market status.